Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $42.22 Average PT from Analysts

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have been assigned a consensus rating of “Hold” from the thirteen brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $42.3333.

A number of analysts have recently commented on the stock. Citizens Jmp lowered shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, August 10th. JonesTrading lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Wedbush boosted their price target on shares of Sionna Therapeutics from $5.00 to $6.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 15th. Raymond James Financial downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “market perform” rating in a research note on Monday, August 10th. Finally, Guggenheim cut Sionna Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 10th.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 115,844 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the transaction, the director owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. The trade was a 4.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the sale, the director owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 403,524 shares of company stock valued at $18,250,367 over the last three months. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SION. Engineers Gate Manager LP acquired a new stake in Sionna Therapeutics in the second quarter valued at $686,000. AXQ Capital LP acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth about $202,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Sionna Therapeutics by 9,056.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,622 shares of the company’s stock worth $467,000 after purchasing an additional 10,506 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at about $1,644,000. Finally, Artia Global Partners LP bought a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at about $5,267,000.

Sionna Therapeutics Stock Performance

Shares of Sionna Therapeutics stock opened at $5.96 on Friday. The business’s 50 day simple moving average is $22.51 and its 200 day simple moving average is $33.54. Sionna Therapeutics has a 52-week low of $4.01 and a 52-week high of $54.97. The firm has a market cap of $269.45 million, a PE ratio of -2.73 and a beta of 0.89.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). As a group, equities research analysts predict that Sionna Therapeutics will post -2.54 EPS for the current year.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disease that affects the lungs and other organs. The company is developing small-molecule therapies designed to address defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is responsible for transporting salt and fluids across cell membranes.

Sionna’s research is centered on nucleotide-binding domain 1 (NBD1) correctors.